160 μg
Sponsors
Insmed Inc.
Conditions
Pulmonary Arterial HypertensionPulmonary Hypertension Associated with Interstitial Lung Disease
Phase 2
An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
Active, not recruitingCTIS2023-505540-19-00
Start: 2023-04-24Target: 27Updated: 2025-02-27
A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension
CompletedCTIS2023-505541-99-00
Start: 2022-06-28End: 2025-03-05Target: 23Updated: 2025-04-02
An Open-Label Extension Study to Assess the Safety, Tolerability, and Effectiveness of the Long-Term use of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension
RecruitingCTIS2023-505539-11-00
Start: 2023-04-06Target: 23Updated: 2025-11-03
Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallelgroup Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
Not yet recruitingCTIS2025-521558-40-00
Target: 73Updated: 2026-01-27
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Not yet recruitingCTIS2025-521769-29-00
Target: 96Updated: 2026-07-01